BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Obtain formulation and manufacturing information
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Queensland Health
Healthtrust
Fuji
Boehringer Ingelheim
Medtronic
US Army
McKinsey
Express Scripts
Federal Trade Commission
Cantor Fitzgerald

Generated: January 19, 2018

DrugPatentWatch Database Preview

Genentech Company Profile

« Back to Dashboard

Summary for Genentech
International Patents:296
US Patents:24
Tradenames:10
Ingredients:6
NDAs:9

Drugs and US Patents for Genentech

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-001 Jan 11, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genentech Inc ESBRIET pirfenidone CAPSULE;ORAL 022535-001 Oct 15, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genentech Inc ESBRIET pirfenidone CAPSULE;ORAL 022535-001 Oct 15, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genentech Inc ESBRIET pirfenidone CAPSULE;ORAL 022535-001 Oct 15, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Genentech Inc COTELLIC cobimetinib fumarate TABLET;ORAL 206192-001 Nov 10, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genentech NUTROPIN DEPOT somatropin recombinant INJECTABLE;INJECTION 021075-001 Dec 22, 1999 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genentech CRESCORMON somatropin INJECTABLE;INJECTION 017992-001 Approved Prior to Jan 1, 1982 DISCN No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-001 Jan 11, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-003 Jan 11, 2017 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-001 Jan 11, 2017 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for Genentech

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Genentech NUTROPIN DEPOT somatropin recombinant INJECTABLE;INJECTION 021075-001 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Genentech NUTROPIN DEPOT somatropin recombinant INJECTABLE;INJECTION 021075-002 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Genentech NUTROPIN somatropin recombinant INJECTABLE;INJECTION 020168-001 Nov 17, 1993 ➤ Subscribe ➤ Subscribe
Genentech NUTROPIN DEPOT somatropin recombinant INJECTABLE;INJECTION 021075-001 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Genentech Inc ESBRIET pirfenidone TABLET;ORAL 208780-003 Jan 11, 2017 ➤ Subscribe ➤ Subscribe
Genentech NUTROPIN DEPOT somatropin recombinant INJECTABLE;INJECTION 021075-003 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Genentech NUTROPIN DEPOT somatropin recombinant INJECTABLE;INJECTION 021075-003 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Genentech NUTROPIN DEPOT somatropin recombinant INJECTABLE;INJECTION 021075-002 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Genentech NUTROPIN DEPOT somatropin recombinant INJECTABLE;INJECTION 021075-003 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Genentech NUTROPIN DEPOT somatropin recombinant INJECTABLE;INJECTION 021075-003 Dec 22, 1999 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for Genentech

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
2,017,166,523 ➤ Subscribe
7,915,250 Azetidines as MEK inhibitors for the treatment of proliferative diseases ➤ Subscribe
9,790,183 Pyridyl inhibitors of hedgehog signalling ➤ Subscribe
9,321,761 Pyridyl inhibitors of hedgehog signalling ➤ Subscribe
9,017,722 Pharmaceutical composition containing as an active ingredient 5-methyl-1-phenyl-2-(1H)-pyridone ➤ Subscribe
7,867,516 Medicinal preparation containing 5-methyl-1-phenyl-2-(1h)-pyridone as active ingredient ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for Genentech Drugs

Supplementary Protection Certificates for Genentech Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1789390/01 Switzerland ➤ Subscribe PRODUCT NAME: VISMODEGIB; REGISTRATION NO/DATE: SWISSMEDIC 62497 30.05.2013
2013024 Lithuania ➤ Subscribe PRODUCT NAME: VISMODEGIBUM; NAT. REGISTRATION NO/DATE: SWISS 62497 01 20130530; FIRST REGISTRATION: EU/1/13/848 20130712
2013000074 Germany ➤ Subscribe PRODUCT NAME: ERIVEDGE - VISMODEGIB; NAT. REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION: SCHWEIZ IKS-NR. 62497 20130530
0130027 00083 Estonia ➤ Subscribe PRODUCT NAME: VISMODEGIIB;REG NO/DATE: K(2013)4550 (LOPLIK) 12.07.2013
0809 Netherlands ➤ Subscribe PRODUCT NAME: COBIMETINIBI, DESGEWENST FARMACEUTISCH AANVAARDBARE ZOUTEN EN SOLVATEN DAARVAN, IN HET BIJZONDER COBIMETINIB HEMIFUMARAAT; REGISTRATION NO/DATE: EU/1/15/1048 20151124
2013 00050 Denmark ➤ Subscribe PRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530
2013 00050 Denmark ➤ Subscribe PRODUCT NAME: VISMODEGIB; NAT. REG. NO/DATE: EU71/13/848 20130712; FIRST REG. NO/DATE: CH 62497 20130530
14/002 Ireland ➤ Subscribe PRODUCT NAME: ERIVEDGE-VISMODEGIB OR A SALT OR SOLVATE THEREOF; NAT REGISTRATION NO/DATE: EU/1/13/848 20130712; FIRST REGISTRATION NO/DATE: 62497 01 20130530
2016 00021 Denmark ➤ Subscribe PRODUCT NAME: COBIMETINIB, EVENTUELT I EN HVILKEN SOM HELST FORM BESKYTTET AF GRUNDPATENTET, DER INDBEFATTER FARMACEUTISK ACCEPTABLE SALTE OG SOLVATER, SAERLIGT COBIMETINIB HEMIFUMARAT; REG. NO/DATE: EU/1/15/1048 20151124
C0021 France ➤ Subscribe PRODUCT NAME: COBIMETINIB,OPTIONNELLEMENT SOUS TOUTE FORME PROTEGEE PAR LE BREVET DE BASE,NOTAMMENT SES SELS ET SOLVATES PHARMACEUTIQUEMENT ACCEPTABLES,EN PARTICULIER L'HEMIFUMARATE DE COBIMETINIB; REGISTRATION NO/DATE: EU/1/15/1048 20151124
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Queensland Health
US Department of Justice
Boehringer Ingelheim
Medtronic
Argus Health
Mallinckrodt
Express Scripts
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot